Reuters logo
BRIEF-AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease
November 2, 2017 / 11:59 AM / 20 days ago

BRIEF-AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for alzheimer's disease

Nov 2 (Reuters) - Ac Immune Ltd

* AC Immune SA to receive milestone payment for anti-tau antibody moving into phase 2 trial for Alzheimer’s Disease

* Ac Immune - ‍upon dosing of first patient in phase 2 trial of RO7105705​, co becomes eligible to get milestone payment of CHF 14 million, expected in Q4 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below